Used in the treatment of advanced renal cell carcinoma (a type of kidney cancer), particularly after failure of prior systemic therapy. It functions as a tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), which helps block the signaling pathways that promote tumor angiogenesis and tumor growth. Axitinib is taken orally and is designed to slow cancer progression by inhibiting the formation of new blood vessels that supply the tumor. It is often used in patients who have not responded to other treatments such as cytokines or sunitinib.